Co-targeting the PI3K and MEK pathways in NSCLC: an in vitro evaluation and mutation prevalence in an Irish patient cohort

被引：0
|
作者：
Heavey, S. [1 ]
Barr, M. P. [1 ,2 ]
Hennessy, B. [3 ]
Toomey, S. [3 ]
Carr, A. [3 ]
Crown, J. [4 ]
Finn, S. [1 ]
Cuffe, S. [1 ,2 ]
O'Byrne, K. J. [5 ]
Gately, K. A. [1 ,2 ]
机构：
[1] Univ Dublin Trinity Coll, Dublin 2, Ireland
[2] St James Hosp, HOPE Directorate, Dublin 8, Ireland
[3] Royal Coll Surgeons Ireland, Dublin 2, Ireland
[4] St Vincents Hosp, Dublin 4, Ireland
[5] Princess Alexandra Hosp, Brisbane, Qld 4102, Australia
来源：
LUNG CANCER | 2014年 / 83卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9
引用
收藏
页码：S4 / S4
页数：1
相关论文
共 50 条
  • [31] TARGETING EGFR AND PI3K PATHWAYS IN OVARIAN CANCER
    Cree, A.
    Glaysher, M.
    Bolton, L.
    Johnson, P.
    Atkey, N.
    Torrance, C.
    ANNALS OF ONCOLOGY, 2012, 23 : 27 - 27
  • [32] Targeting EGFR and PI3K pathways in ovarian cancer
    Glaysher, S.
    Bolton, L. M.
    Johnson, P.
    Atkey, N.
    Dyson, M.
    Torrance, C.
    Cree, I. A.
    BRITISH JOURNAL OF CANCER, 2013, 109 (07) : 1786 - 1794
  • [33] Targeting PI3K/AKT and MEK/ERK pathways for synergic effects on improving features of peripheral diabetic neuropathy
    Pham, Vuong M.
    JOURNAL OF DIABETES INVESTIGATION, 2024, 15 (11) : 1537 - 1544
  • [34] Ganetespib Resistance in KRAS Mutant NSCLC Is Mediated through Reactivation of the RAF/MEK/ERK and PI3K/MTOR Pathways
    Chatterjee, Suman
    Burns, Timothy F.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S608 - S609
  • [35] Targeting the RAF/MEK/ERK, PI3K/AKT and P53 pathways in hematopoietic drug resistance
    McCubrey, James A.
    Steelman, Linda S.
    Franklin, Richard A.
    Abrams, Steven L.
    Chappell, William H.
    Wong, Ellis W. T.
    Lehmann, Brian D.
    Terrian, David M.
    Basecke, Jorg
    Stivala, Franca
    Libra, Massimo
    Evangelisti, Camilla
    Martelli, Alberto M.
    ADVANCES IN ENZYME REGULATION, VOL 47, 2007, 47 : 64 - +
  • [36] Co-targeting asparagine and glutamine metabolism is a viable treatment strategy for PI3K/PTEN mutated cervical cancer
    Gabriel, Nishanth Noel
    Muhammad, Naoshad
    Cho, Kevin
    Jayachandran, Kay
    Zhang, Jin
    Patti, Gary
    Schwarz, Julie
    CANCER RESEARCH, 2024, 84 (06)
  • [37] PIK3CA mutations and response to PI3K and MEK targeted therapies in NSCLC
    Heavey, S.
    Davies, M. A.
    O'Byrne, K. J.
    Gately, K.
    LUNG CANCER, 2013, 79 : S3 - S3
  • [38] In Vitro Treatment of Melanoma Brain Metastasis by Simultaneously Targeting the MAPK and PI3K Signaling Pathways
    Daphu, Inderjit
    Horn, Sindre
    Stieber, Daniel
    Varughese, Jobin K.
    Spriet, Endy
    Dale, Hege Avsnes
    Skaftnesmo, Kai Ove
    Bjerkvig, Rolf
    Thorsen, Frits
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2014, 15 (05) : 8773 - 8794
  • [39] Supramolecular fusion nanotherapeutic mediated synergistic inhibition of PI3K and MEK pathways
    Chandrasekar, Vineethkrishna
    Natarajan, Siva Kumar
    Sengupta, Shiladitya
    Kulkarni, Ashish
    CANCER RESEARCH, 2016, 76
  • [40] Co-targeting toll-like receptor and PI3K survival signaling pathways in stem-like castration resistant prostate cancer cells
    Oseni, Saheed Oluwasina
    Branly, Rolando
    Pavlovic, Mirjana
    Kumi-Diaka, James
    CANCER RESEARCH, 2018, 78 (13)
12345